AstraZeneca Plc (NASDAQ:AZN) on Wednesday reported first-quarter 2026 results that topped Wall Street estimates, driven by strong oncology and rare disease performance.
The company posted revenue of $15.29 billion, up 13% year over year, or 8% at constant currency (CC), beating the consensus estimate of $14.94 billion. Adjusted earnings came in at $2.58 per share, ahead of expectations of $2.51.
Oncology Drives Growth
AstraZeneca’s oncology portfolio accounted for 45% of product revenue, rising 20% year over year, or 16% CC, to $6.79 billion.
Tagrisso sales increased 9% (5% CC) to $1.83 billion. Imfinzi revenue rose 34% (30% CC) to $1.69 billion, Calquence sales climbed 21% (17% CC) to $923 million, and Enhertu revenue jumped 40% (34% CC) to $831 million.
Mixed Trends Across Other Segments
Cardiovascular, renal, and metabolism product revenue totaled $3.24 billion, representing 21% of product sales, but declined 7% at constant currency due to foreign exchange headwinds. Farxiga product revenue, the segment’s top-selling drug, …